Skip to content

Amsterdam/Aarhus Chronic Thromboembolic Pulmonary Hypertension / Chronic Thromboembolic Disease (CTEPH/CTED) Cohort (2A3C) Study

Amsterdam/Aarhus Chronic Thromboembolic Pulmonary Hypertension / Chronic Thromboembolic Disease (CTEPH/CTED) Cohort (2A3C) Study - 2A3C Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON47632
Enrollment
200
Registered
2018-05-24
Start date
2017-09-11
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Thromboembolic Pulmonary Hypertension

Interventions

Chronic Thromboembolic Pulmonary Hypertension
Hemodynamics
Magnetic Resonance Imaging

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Diagnosis of CTEPH or CTED (according to ESC/ERS guidelines (11)) - Scheduled for evaluation to determine possibility of PEA or BPA - Age > 18

Exclusion criteria

Exclusion criteria: - Pacemaker or other metal objects in the body - Severe claustrophobia - Severe renal insufficiency (eGFR

Design outcomes

Primary

MeasureTime frame
Main study parameters/endpoints: This is an observational study evaluating determinants of a persistent response to BPA or PEA. Main study parameter/endpoint is change in extracellular volume fraction after unloading of the RV after PEA or BPA. This is measured calculated from pre and post contrast T1 relaxation times measured by MR imaging.

Secondary

MeasureTime frame
- Change in RV function and volumes after PEA or BPA. This is measured by MR imaging (RV ejection fraction, end diastolic volume, end systolic volume) and right heart catheterization (end systolic elastance, RV-Arterial coupling) - Change in lung perfusion defects before and after PEA measured by MR perfusion - Change in serum levels of biomarkers of fibrosis and extracellular matrix - Change in platelet transcriptomes - Change in exercise capacity (peak oxygen uptake during cardiopulmonary exercise testing, or CPET, and distance walked in 6 minutes) and gas exchange during CPET (ventilatory efficiency, pulse oximetry) - Change in quality of life - Change in diffusion capacity

Countries

Denmark

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)